ARTV
HEALTHCAREArtiva Biotherapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving ARTV Today?
No stock-specific AI insight has been generated for ARTV yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$12.39
Fundamentals
Trading
ARTV News
23 articles- Artiva: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA (NASDAQ:ARTV)Seeking Alpha·May 8, 2026
- Artiva Biotherapeutics Announces $300 Million Equity OfferingTipRanks·May 8, 2026
- Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeGlobeNewswire Inc.·Apr 28, 2026
- Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans?Yahoo Finance·Apr 17, 2026
- Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at NeedhamMarketbeat·Apr 15, 2026
- Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire Inc.·Apr 8, 2026
- Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business HighlightsYahoo Finance·Mar 10, 2026
- Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data UpdateMarketbeat·Mar 4, 2026
- Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 25, 2026
- Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement GrantYahoo Finance·Feb 24, 2026
- AtaiBeckley names Michael Faerm as finance chiefProactive Investors·Feb 19, 2026
- Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of DirectorsYahoo Finance·Feb 19, 2026
- Undervalued Penny Stocks To Consider In January 2026Yahoo Finance·Jan 26, 2026
- Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHLYahoo Finance·Jan 21, 2026
- Artiva Biotherapeutics (ARTV): Evaluating Valuation After CEO’s Latest Insider Share SaleYahoo Finance·Dec 19, 2025
- Rocket Pharmaceuticals Leads Our Trio Of Penny Stock ContendersYahoo Finance·Dec 17, 2025
- Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy’ StocksYahoo Finance·Dec 14, 2025
- Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune DiseaseYahoo Finance·Nov 12, 2025
- Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsYahoo Finance·Nov 12, 2025
- Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®Yahoo Finance·Nov 3, 2025
- Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in NovemberYahoo Finance·Oct 30, 2025
- 3 Promising Penny Stocks With Market Caps Under $200MYahoo Finance·Oct 29, 2025
- Artiva Biotherapeutics Prioritizes Refractory Rheumatoid Arthritis as Lead Indication for AlloNK (AB-101)Yahoo Finance·Oct 22, 2025
All 23 articles loaded
Price Data
52-Week Range
$12.39
Fundamentals
Trading
About Artiva Biotherapeutics Inc
Artiva Biotherapeutics, Inc. is a cutting-edge biotechnology company dedicated to advancing next-generation cell therapies for cancer treatment through its proprietary platform, which enhances natural killer (NK) cell therapies. The company boasts a robust pipeline targeting various hematologic and solid tumors, underscoring its strong commitment to innovation in the immuno-oncology space. With a focus on scientific excellence and strategic collaborations, Artiva is well-positioned to drive transformative advancements in cancer care, aiming to significantly improve patient outcomes as its promising therapeutic candidates progress through clinical development.